AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD

BACKGROUND: AMPLIFY assessed the efficacy and safety of aclidinium bromide/formoterol fumarate (AB/FF) vs its monocomponents and tiotropium (TIO) in patients with moderate-to-very severe symptomatic COPD (NCT02796677). METHODS: In this 24-week, Phase III, double-dummy, active-controlled study, sympt...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Int J Chron Obstruct Pulmon Dis
Главные авторы: Sethi, Sanjay, Kerwin, Edward, Watz, Henrik, Ferguson, Gary T, Mroz, Robert M, Segarra, Rosa, Molins, Eduard, Jarreta, Diana, Garcia Gil, Esther
Формат: Artigo
Язык:Inglês
Опубликовано: Dove Medical Press 2019
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6435124/
https://ncbi.nlm.nih.gov/pubmed/30962681
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S189138
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы